Navigation Links
Hospira Launches Generic Oxaliplatin Injection
Date:8/11/2009

LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States. The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin injection is one of the first generic versions of this drug to come in solution form. The innovator drug is also in solution form. Oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor, and in the treatment of advanced colorectal cancer.

"Hospira's launch of oxaliplatin injection in solution form gives our customers a generic alternative of this critical medication in the formulation they seek," said Sue Hazelwood, vice president and general manager, alternate site, U.S., Hospira. "This is another example of Hospira's dedication to providing high-quality products that will reduce costs in the oncology space."

Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage(R) drug delivery system and iSecure(R) prefilled syringes. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.

                 Private Securities Litigation Reform Act of 1995 --
                  A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Reports Second-Quarter 2009 Results
2. ICU Medical, Inc. to Acquire Hospiras Critical Care Product Line
3. Hospira Receives FDA Approval for Azithromycin for Injection
4. Hospira to Host Conference Call for Second-Quarter 2009 Results
5. Hospira Highlights Five Years of Progress and Future Opportunities at Its 2009 Annual Meeting of Shareholders
6. Hospira to Present at Bank of America and Merrill Lynch 2009 Health Care Conference May 13
7. Hospira Launches Biologics Clock and Web Resource to Raise Awareness of Potential Biogenerics Impact
8. Hospira Reports First-Quarter 2009 Results
9. Hospira to Host Conference Call for First-Quarter 2009 Results
10. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
11. Hospira Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: